Articles
Benitec treats first patient in HCV trial
Benitec Biopharma (ASX:BLT) has commenced a phase I/IIa trial of ddRNAi-based therapeutic TT-034, marking the first time the treatment candidate has been used in humans. [ + ]
How do Australians engage with science?
A national survey on Australians' engagement with science has found that the majority have extremely positive attitudes about science and technology, though they're not always clear about the details. [ + ]
Adopting immunity
Drs Leighton Clancy and Emily Blyth are developing and conducting clinical trials on virus-specific and tumour-specific T cells with the ultimate goal of producing an improved treatment package for bone marrow transplant patients. [ + ]
Australia rises to the challenge of creating synthetic yeast
Australia has joined the Yeast 2.0 project, an international effort to create the world's first ever synthetic complex organism: a particular strain of yeast. [ + ]
Sienna reagent and cancer biomarker registered with FDA
The US FDA has registered the lead product of Melbourne-based biotech company Sienna Cancer Diagnostics - the antibody SCD-A7.
[ + ]Novogen to test SBPs in prostate cancer
Novogen (ASX:NRT) has identified a number of super-benzopyran (SBP) compounds with a potent effect against prostate cancer cells in vitro, and aims to trial the lead candidate in 2015. [ + ]
Prima's US patent for CVac allowed
The US patent office has granted Prima BioMed a Notice of Allowance covering a patent application protecting cancer treatment candidate CVac. [ + ]
Phosphagenics' opioid patch eases pain in horses
All six injured thoroughbred racehorses treated with Phosphagenics' TPM/oxycodone patch during a pilot trial recovered from pain within 48 hours. [ + ]
Heating block systems support synthesis research
Monash University's School of Chemistry has invested in a range of Asynt DrySyn Multi heating block systems to support its groundbreaking research in photovoltaics, water splitting and nanoimaging. [ + ]
The crop scientist
Professor Graham Farquhar speaks about a distinguished research career that spans a range of fields and interests, from the development of models for photosynthesis and water use in plants to contemplating becoming a professional dancer and advising on global change. [ + ]
Clinuvel gets orphan status for Scenesse in HHD
Clinuvel (ASX:CUV) has received EMA orphan drug designation for Scenesse in Hailey-Hailey Disease, and has revealed it expects the agency to complete its review of the product in EPP by October. [ + ]
Heavy mouse enables hard-hitting research
Scientists from the University of Cambridge have created the world's first animal enriched with heavy but non-radioactive isotopes. The 'heavy' mouse has enabled the scientists to capture in unprecedented detail the molecular structure of natural tissue by reading the magnetism inherent in the isotopes. [ + ]
Single-cell analysis inspired by microchips
US and Korean researchers have developed a device, similar to a random-access memory (RAM) chip, which moves cells rather than electrons. The device could be scaled up to sort and store hundreds of thousands of individual living cells in a matter of minutes. [ + ]
Phylogica hit with two market setbacks
Phylogica's (ASX:PYC) research partner Janssen Pharmaceuticals has elected not to license the outcome of their collaboration and a Phylogica licensee has filed for bankruptcy. [ + ]
A powerful body scanner for an advanced imaging facility
The University of Queensland's Centre for Advanced Imaging has acquired an $11 million 7 T MRI scanner, said to be the most powerful body scanner in the Southern Hemisphere. [ + ]
